Join our daily newsletter At The Bell to receive exclusive market insights
- Impedimed (IPD) shares soar on Monday after the US National Comprehensive Cancer Network (NCCN) recommends regular screenings with bioimpedance spectroscopy
- This marks the first time the NCCN’s Clinical Practice Guidelines in Oncology for Survivorship has included bioimpedance spectroscopy
- The NCCN guidelines are the globally-recognised standard for clinical direction and policy in cancer care to improve patient outcomes
- ImpediMed currently has the only FDA-cleared bioimpedance spectroscopy technology for the assessment of lymphoedema
- ImpediMed shares skyrocket 55.93 per cent, trading at 9.2 cents at 1:45 pm AEDT
Impedimed (IPD) shares soared on Monday after the US National Comprehensive Cancer Network (NCCN) recommended regular screenings with bioimpedance spectroscopy (BIS).
The NCCN released a new version of its Clinical Practice Guidelines in Oncology for Survivorship which, for the first time, included BIS.
The NCCN guidelines are the globally-recognised standard for clinical direction and policy in cancer care, with the goal of improving patient care and outcomes.
The guidelines apply to all cancer survivors and recommend that cancer survivors at risk of lymphoedema undergo lymphoedema screening at regular intervals to identify early signs.
ImpediMed currently has the only FDA-cleared BIS technology for the assessment of lymphoedema.
The company’s SOZO Digital Health Platform is broadly accepted and recognised for the effective and accurate screening of lymphoedema.
SOZO is the world’s most advanced, non-invasive bioimpedance spectroscopy device and delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. The device is FDA-cleared and CE-marked for the early detection of secondary lymphoedema and provides fluid status.
“The recommendation in the NCCN Guidelines for the use of bioimpedance spectroscopy technology is a major validating moment for the company,” ImpediMed Managing Director and CEO Richard Valencia said.
“We will take the information in these updated NCCN Guidelines and immediately integrate it into our reimbursement strategy to expand coverage of SOZO testing for lymphoedema.”
Mr Valencia told investors the company’s near-term focus remained on leveraging its clinical evidence, market position, and these guidelines to drive the growth of its solution for breast cancer-related lymphoedema.
“Longer-term, these guidelines also support an opportunity to expand into other cancer types, broaden our footprint in oncology, and benefit even more patients,” he said.
ImpediMed shares skyrocketed 55.93 per cent to trade at 9.2 cents at 1:45 pm AEDT.
